| Steven A Khalil, MD | |
|
999 N Curtis Rd Ste 415, Boise, ID 83706-1334 | |
| (208) 302-2600 | |
| (208) 302-2625 |
| Full Name | Steven A Khalil |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 23 Years |
| Location | 999 N Curtis Rd Ste 415, Boise, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245452606 | NPI | - | NPPES |
| 15036 | Other | UNIVERSAL HEALTHCARE | |
| 15633301 | Other | FL | CITRUS HEALTHCARE |
| 308765 | Other | FL | AVMED |
| 326363 | Other | FL | AMERIGROUP |
| 409903 | Other | FL | WELLCARE |
| 7645894 | Other | FL | AETNA |
| NPI | Other | FL | PHYSICAINS UNITED PLAN |
| 17 03735 | Other | FL | UHC |
| 15351 | Other | FL | BCBS OF FLORIDA |
| 8556767 | Other | FL | CIGNA |
| AF509 | Other | FL | MEDICARE |
| ME98528 | Other | FL | LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2086S0102X | Surgery - Surgical Critical Care | ME98528 (Florida) | Secondary |
| 2086S0102X | Surgery - Surgical Critical Care | M-17692 (Idaho) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension Sacred Heart Bay | Panama city, FL | Hospital |
| Shands Jacksonville | Jacksonville, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sacred Heart Health System Inc | 3779491386 | 355 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.
Among individuals who survive a trauma that resulted in the loss of a close friend or loved one, symptoms of post-traumatic stress disorder can predict complicated grief—a sense of persistent sadness and an inability to cope—years after the trauma, according to research published by the American Psychological Association.
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
› Verified 2 days ago
| Entity Name | Halifax Healthcare Systems Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245283530 PECOS PAC ID: 1254238090 Enrollment ID: O20031218000443 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.
Among individuals who survive a trauma that resulted in the loss of a close friend or loved one, symptoms of post-traumatic stress disorder can predict complicated grief—a sense of persistent sadness and an inability to cope—years after the trauma, according to research published by the American Psychological Association.
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
› Verified 2 days ago
| Entity Name | University Of Florida Jacksonville Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144276452 PECOS PAC ID: 9133025869 Enrollment ID: O20040128000786 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.
Among individuals who survive a trauma that resulted in the loss of a close friend or loved one, symptoms of post-traumatic stress disorder can predict complicated grief—a sense of persistent sadness and an inability to cope—years after the trauma, according to research published by the American Psychological Association.
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
› Verified 2 days ago
| Entity Name | University Of Florida Jacksonville Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326208695 PECOS PAC ID: 9133025869 Enrollment ID: O20040204000616 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.
Among individuals who survive a trauma that resulted in the loss of a close friend or loved one, symptoms of post-traumatic stress disorder can predict complicated grief—a sense of persistent sadness and an inability to cope—years after the trauma, according to research published by the American Psychological Association.
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
› Verified 2 days ago
| Entity Name | Intensive Care Consortium Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629019062 PECOS PAC ID: 0244269413 Enrollment ID: O20050808000883 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.
Among individuals who survive a trauma that resulted in the loss of a close friend or loved one, symptoms of post-traumatic stress disorder can predict complicated grief—a sense of persistent sadness and an inability to cope—years after the trauma, according to research published by the American Psychological Association.
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
› Verified 2 days ago
| Entity Name | Sacred Heart Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962453308 PECOS PAC ID: 3779491386 Enrollment ID: O20051015000049 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.
Among individuals who survive a trauma that resulted in the loss of a close friend or loved one, symptoms of post-traumatic stress disorder can predict complicated grief—a sense of persistent sadness and an inability to cope—years after the trauma, according to research published by the American Psychological Association.
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
› Verified 2 days ago
| Entity Name | St Vincent's Ambulatory Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417987124 PECOS PAC ID: 2860411188 Enrollment ID: O20051116000430 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.
Among individuals who survive a trauma that resulted in the loss of a close friend or loved one, symptoms of post-traumatic stress disorder can predict complicated grief—a sense of persistent sadness and an inability to cope—years after the trauma, according to research published by the American Psychological Association.
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
› Verified 2 days ago
| Entity Name | Sound Physicians Of Florida Iv, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740633635 PECOS PAC ID: 6002198082 Enrollment ID: O20170127000352 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.
Among individuals who survive a trauma that resulted in the loss of a close friend or loved one, symptoms of post-traumatic stress disorder can predict complicated grief—a sense of persistent sadness and an inability to cope—years after the trauma, according to research published by the American Psychological Association.
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
› Verified 2 days ago
| Entity Name | Continuum Medical Solutions Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003464033 PECOS PAC ID: 6608204169 Enrollment ID: O20200316001034 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.
Among individuals who survive a trauma that resulted in the loss of a close friend or loved one, symptoms of post-traumatic stress disorder can predict complicated grief—a sense of persistent sadness and an inability to cope—years after the trauma, according to research published by the American Psychological Association.
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven A Khalil, MD 4205 Belfort Rd Ste 4015, Jacksonville, FL 32216-3623 Ph: (904) 450-6063 | Steven A Khalil, MD 999 N Curtis Rd Ste 415, Boise, ID 83706-1334 Ph: (208) 302-2600 |
News Archive
Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that patient enrollment has begun in a multicenter, open-label clinical study of CMX001 (the CMX001-350 study) for the treatment of life-threatening or serious conditions caused by double-stranded DNA (dsDNA) viruses.
In a mouse study, scientists at Mayo Clinic Florida have demonstrated the feasibility of a promising new strategy for treating human type 2 diabetes, which affects more than 200 million people worldwide.
Among individuals who survive a trauma that resulted in the loss of a close friend or loved one, symptoms of post-traumatic stress disorder can predict complicated grief—a sense of persistent sadness and an inability to cope—years after the trauma, according to research published by the American Psychological Association.
Vical Incorporated announced today that the company's Vaxfectin® adjuvant has significantly boosted the immune response of DNA-based vaccines against a range of pathogens and cancer in preclinical models from rodents to non-human primates. Vaxfectin® has demonstrated similar effects with protein- and peptide-based vaccines in preclinical models.
› Verified 2 days ago
Dr. Craig B. Bass, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 250 Bobwhite Ct, # 275, Boise, ID 83706 Phone: 208-333-0200 Fax: 208-333-0399 | |
Aziz George Munayirji, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 999 N Curtis Rd, Suite 415, Boise, ID 83706 Phone: 208-367-7676 Fax: 208-367-5595 | |
John M Livingston, M.D. Surgery Medicare: Not Enrolled in Medicare Practice Location: 8756 W Emerald St, Suite 136, Boise, ID 83704 Phone: 208-853-3051 Fax: 208-853-3053 | |
Jason A Kemp, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 222 N 2nd St, Suite 202, Boise, ID 83702 Phone: 208-381-6390 Fax: 208-381-6395 | |
Dr. Patrick Cole, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1070 N Curtis Rd Ste 135, Boise, ID 83706 Phone: 208-947-5390 Fax: 208-947-3465 | |
Dr. Graham W Donald, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 333 N 1st St Ste 280, Boise, ID 83702 Phone: 208-345-6545 Fax: 208-345-1213 | |
Courtney Alyson Green, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 999 N Curtis Rd Ste 415, Boise, ID 83706 Phone: 208-302-2600 Fax: 208-302-2625 |